Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $96.38M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 1.66M
Average 2.44M
Returns on capital
Neuronetics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-174.3%
avg -71.0%
ROIC
-27.0%
avg -34.1%
ROA
-27.6%
avg -31.0%
Analysis
ROIC is currently the strongest return metric at -27.0% versus its period average of -34.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Daniel L. Reuvers | President, Chief Executive Officer & Director | USD 927.61K | 63 | 0 | <0.01% |
Cory S. Anderson | Executive Vice President & General Manager of Greenbrook | — | 49 | — | — |
Nir Naor | Executive VP, CFO, Corporate Secretary, Principal Financial and Accounting Officer & Treasurer | — | 51 | 0 | <0.01% |
Robert Greene | Senior Vice President of Sales | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 23, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
16
$4.93M
Sells
17
$4.76M
Net Transaction Value
+$169,175.53
Net buying
Most Active
Chernett Jorey
22 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 13, 26Nov 13, 2026 | Chernett Jorey Direct | Sell | $2.5M$2,515,108.65 |
| Nov 12, 26Nov 12, 2026 | Chernett Jorey Direct | Sell | $1M$1,010,781.20 |
| Nov 11, 26Nov 11, 2026 | Chernett Jorey Direct | Sell | $139.7K$139,678.77 |
| Nov 9, 26Nov 9, 2026 | Chernett Jorey Direct | Sell | $214.2K$214,155.54 |
| Nov 9, 26Nov 9, 2026 | Chernett Jorey Direct | Buy | $79.6K$79,600.00 |
| Nov 6, 26Nov 6, 2026 | Chernett Jorey Direct | Sell | $599.4K$599,421.56 |
| Oct 30, 26Oct 30, 2026 | Chernett Jorey Direct | Buy | $40.9K$40,860.00 |
| Aug 14, 26Aug 14, 2026 | Chernett Jorey Direct | Buy | $44.2K$44,240.00 |
| Aug 13, 26Aug 13, 2026 | Chernett Jorey Direct | Sell | $500$500.00 |
| Jul 14, 26Jul 14, 2026 | Chernett Jorey Direct | Buy | $62.3K$62,300.00 |
1–10 of 33
Summary
Insiders reported 16 buys worth $4.93M and 17 sells worth $4.76M over the last 12 months. That adds up to net buying of $169,175.53. Chernett Jorey was the most active insider with 22 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +31.8% | +9.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +31.8% over three years. Forward estimates point to Revenue at +9.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Neuronetics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about STIM's management, answered from reported figures.
Who manages STIM?
Neuronetics, Inc. (STIM) lists 4 active executives. The top listed executive is Cory S. Anderson, Executive Vice President & General Manager of Greenbrook.
Are STIM insiders buying or selling?
Recent insider activity shows net selling of $14.59M.
Continue the stock analysis
Jump to another research area for this company.